Skip to main content
Erschienen in: Strahlentherapie und Onkologie 3/2016

01.03.2016 | Original Article

Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients

verfasst von: P. M. Putora, D. Engeler, S. R. Haile, N. Graf, K. Buchauer, H. P. Schmid, L. Plasswilm

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

For localized prostate cancer, treatment options include external beam radiotherapy (EBRT), radical prostatectomy (RP), and brachytherapy (BT). Erectile dysfunction (ED) is a common side-effect. Our aim was to evaluate penile erectile function (EF) before and after BT, EBRT, or RP using a validated self-administered quality-of-life survey from a prospective registry.

Material and methods

Analysis included 478 patients undergoing RP (n = 252), EBRT (n = 91), and BT (n = 135) with at least 1 year of follow-up and EF documented using IIEF-5 scores at baseline, 6 weeks, 6 months, 1 year, and annually thereafter.

Results

Differences among treatments were most pronounced among patients with no or mild initial ED (IIEF-5 ≥ 17). Overall, corrected for baseline EF and age, BT was associated with higher IIEF-5 scores than RP (+ 7.8 IIEF-5 score) or EBRT (+ 3.1 IIEF-5 score). EBRT was associated with better IIEF-5 scores than RP (+ 4.7 IIEF-5 score). In patients undergoing EBRT or RP with bilateral nerve sparing (NS), recovery of EF was observed and during follow-up, the differences to BT were not statistically significant. Overall age had a negative impact on EF preservation (corrected for baseline IIEF).

Conclusion

In our series, EF was adversely affected by each treatment modality. Considered overall, BT provided the best EF preservation in comparison to EBRT or RP.
Literatur
1.
2.
Zurück zum Zitat Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:435–448CrossRefPubMed Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:435–448CrossRefPubMed
3.
Zurück zum Zitat Eble MJ (2014) Bevölkerungsbasierte Analyse von Komplikationen nach lokaler Therapie des Prostatakarzinoms. Strahlenther Onkol 190:594–596CrossRefPubMed Eble MJ (2014) Bevölkerungsbasierte Analyse von Komplikationen nach lokaler Therapie des Prostatakarzinoms. Strahlenther Onkol 190:594–596CrossRefPubMed
4.
Zurück zum Zitat Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL (2003) General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 21:1147–1154CrossRefPubMed Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL (2003) General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 21:1147–1154CrossRefPubMed
6.
Zurück zum Zitat Wyler SF, Engeler DS, Seelentag W, Ries G, Schmid HP (2009) Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. Urol Int 82:17–23. doi:10.1159/000176019 CrossRefPubMed Wyler SF, Engeler DS, Seelentag W, Ries G, Schmid HP (2009) Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. Urol Int 82:17–23. doi:10.​1159/​000176019 CrossRefPubMed
7.
Zurück zum Zitat Salomon L, Saint F, Anastasiadis AG, Sebe P, Chopin D, Abbou CC (2003) Combined reporting of cancer control and functional results of radical prostatectomy. Eur Urol 44:656–660CrossRefPubMed Salomon L, Saint F, Anastasiadis AG, Sebe P, Chopin D, Abbou CC (2003) Combined reporting of cancer control and functional results of radical prostatectomy. Eur Urol 44:656–660CrossRefPubMed
8.
Zurück zum Zitat Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436–445. doi:10.1056/NEJMoa1209978 PubMedCentralCrossRefPubMed Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436–445. doi:10.​1056/​NEJMoa1209978 PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Moinpour CM, Hayden KA, Unger JM, Thompson IM Jr, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED, Southwest Oncology G (2008) Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 26:112–120. doi:10.1200/JCO.2006.10.4505 CrossRefPubMed Moinpour CM, Hayden KA, Unger JM, Thompson IM Jr, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED, Southwest Oncology G (2008) Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 26:112–120. doi:10.​1200/​JCO.​2006.​10.​4505 CrossRefPubMed
10.
Zurück zum Zitat Dolezel M, Odrazka K, Zouhar M, Vaculikova M, Sefrova J, Jansa J, Paluska P, Kohlova T, Vanasek J, Kovarik J (2015) Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer. Strahlenther Onkol 191:338–348CrossRefPubMed Dolezel M, Odrazka K, Zouhar M, Vaculikova M, Sefrova J, Jansa J, Paluska P, Kohlova T, Vanasek J, Kovarik J (2015) Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer. Strahlenther Onkol 191:338–348CrossRefPubMed
11.
Zurück zum Zitat Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, Johansson E, Stattin P, Fransson P (2015) Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. doi:10.1111/bju.13179 Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, Johansson E, Stattin P, Fransson P (2015) Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. doi:10.​1111/​bju.​13179
12.
Zurück zum Zitat Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC (2012) A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 61:664–675. doi:10.1016/j.eururo.2011.11.053 CrossRefPubMed Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC (2012) A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 61:664–675. doi:10.​1016/​j.​eururo.​2011.​11.​053 CrossRefPubMed
13.
Zurück zum Zitat Anandadas CN, Clarke NW, Davidson SE, O’Reilly PH, Logue JP, Gilmore L, Swindell R, Brough RJ, Wemyss-Holden GD, Lau MW, Javle PM, Ramani VA, Wylie JP, Collins GN, Brown S, Cowan RA, North West Uro-oncology G (2011) Early prostate cancer–which treatment do men prefer and why? BJU Int 107:1762–1768. doi:10.1111/j.1464-410X.2010.09833.x CrossRefPubMed Anandadas CN, Clarke NW, Davidson SE, O’Reilly PH, Logue JP, Gilmore L, Swindell R, Brough RJ, Wemyss-Holden GD, Lau MW, Javle PM, Ramani VA, Wylie JP, Collins GN, Brown S, Cowan RA, North West Uro-oncology G (2011) Early prostate cancer–which treatment do men prefer and why? BJU Int 107:1762–1768. doi:10.​1111/​j.​1464-410X.​2010.​09833.​x CrossRefPubMed
14.
Zurück zum Zitat Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822–830CrossRefPubMed Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822–830CrossRefPubMed
15.
Zurück zum Zitat Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319–326CrossRefPubMed Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319–326CrossRefPubMed
16.
Zurück zum Zitat Ramanathan R, Mulhall J, Rao S, Leung R, Martinez Salamanca JI, Mandhani A, Tewari A (2007) Predictive correlation between the International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM): implications for calculating a derived SHIM for clinical use. J Sex Med 4:1336–1344CrossRefPubMed Ramanathan R, Mulhall J, Rao S, Leung R, Martinez Salamanca JI, Mandhani A, Tewari A (2007) Predictive correlation between the International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM): implications for calculating a derived SHIM for clinical use. J Sex Med 4:1336–1344CrossRefPubMed
17.
Zurück zum Zitat Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65–70 Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65–70
18.
Zurück zum Zitat R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
19.
Zurück zum Zitat Bates D Mächler M, Bolker B (2013) lme4: Linear mixed-effects models using S4 classes. R package version 0.999999-2 Bates D Mächler M, Bolker B (2013) lme4: Linear mixed-effects models using S4 classes. R package version 0.999999-2
20.
Zurück zum Zitat Hothorn T, Bretz F, Westfall P (2008) Simultaneous inference in General Parametric Models. Biom J 50:346–336CrossRefPubMed Hothorn T, Bretz F, Westfall P (2008) Simultaneous inference in General Parametric Models. Biom J 50:346–336CrossRefPubMed
21.
Zurück zum Zitat van Tol-Geerdink JJ, Willem Leer J, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, Alfred Witjes J, Stalmeier PF (2013) Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU Int 111:564–573. doi:10.1111/j.1464-410X.2012.11402.x CrossRefPubMed van Tol-Geerdink JJ, Willem Leer J, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, Alfred Witjes J, Stalmeier PF (2013) Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU Int 111:564–573. doi:10.​1111/​j.​1464-410X.​2012.​11402.​x CrossRefPubMed
22.
Zurück zum Zitat Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261. doi:10.1056/NEJMoa074311 CrossRefPubMed Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261. doi:10.​1056/​NEJMoa074311 CrossRefPubMed
25.
Zurück zum Zitat Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213. doi:10.1056/NEJMoa1113162 PubMedCentralCrossRefPubMed Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213. doi:10.​1056/​NEJMoa1113162 PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, Patel HR, Chevallier D, Krajka K, Henneges C, Dickson R, Buttner H (2014) Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a Randomised Placebo-controlled Study (REACTT). Eur Urol 65:587–596. doi:10.1016/j.eururo.2013.09.051 CrossRefPubMed Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, Patel HR, Chevallier D, Krajka K, Henneges C, Dickson R, Buttner H (2014) Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a Randomised Placebo-controlled Study (REACTT). Eur Urol 65:587–596. doi:10.​1016/​j.​eururo.​2013.​09.​051 CrossRefPubMed
27.
Zurück zum Zitat Turner SL, Adams K, Bull CA, Berry MP (1999) Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. Urology 54:124–129CrossRefPubMed Turner SL, Adams K, Bull CA, Berry MP (1999) Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. Urology 54:124–129CrossRefPubMed
28.
Zurück zum Zitat Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85:2460–2468CrossRefPubMed Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85:2460–2468CrossRefPubMed
30.
Zurück zum Zitat Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW (2001) Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50:1235–1242CrossRefPubMed Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW (2001) Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50:1235–1242CrossRefPubMed
35.
Zurück zum Zitat Marina O, Warner J, Ye H, Grills IS, Shah C, Wallace M, Gustafson GS, Brabbins DS, Martinez AA, Krauss DJ (2014) An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer. Brachytherapy 13:163–168. doi:10.1016/j.brachy.2013.10.006 CrossRefPubMed Marina O, Warner J, Ye H, Grills IS, Shah C, Wallace M, Gustafson GS, Brabbins DS, Martinez AA, Krauss DJ (2014) An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer. Brachytherapy 13:163–168. doi:10.​1016/​j.​brachy.​2013.​10.​006 CrossRefPubMed
36.
Zurück zum Zitat Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE (2007) Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 109:2239–2247. doi:10.1002/cncr.22676 CrossRefPubMed Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE (2007) Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 109:2239–2247. doi:10.​1002/​cncr.​22676 CrossRefPubMed
37.
Zurück zum Zitat Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Ponce de Leon J, Craven-Bratle J, Suarez JF, Boladeras A, Pont A, Ayala A, Sancho G, Martinez E, Alonso J, Ferrer M (2010) Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 28:4687–4696. doi:10.1200/JCO.2009.25.3245 CrossRefPubMed Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Ponce de Leon J, Craven-Bratle J, Suarez JF, Boladeras A, Pont A, Ayala A, Sancho G, Martinez E, Alonso J, Ferrer M (2010) Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 28:4687–4696. doi:10.​1200/​JCO.​2009.​25.​3245 CrossRefPubMed
38.
Zurück zum Zitat Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 163:460–463CrossRefPubMed Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 163:460–463CrossRefPubMed
39.
Zurück zum Zitat Nishimura S, Yorozu A, Ohashi T, Sakayori M, Yagi Y, Nishiyama T, Saito S, Shiraishi Y, Yoshida K, Toya K, Shigematsu N (2013) Five-year potency preservation after iodine-125 prostate brachytherapy. Int J Clin Oncol. doi:10.1007/s10147-013-0632-8 Nishimura S, Yorozu A, Ohashi T, Sakayori M, Yagi Y, Nishiyama T, Saito S, Shiraishi Y, Yoshida K, Toya K, Shigematsu N (2013) Five-year potency preservation after iodine-125 prostate brachytherapy. Int J Clin Oncol. doi:10.​1007/​s10147-013-0632-8
40.
Zurück zum Zitat Matsushima M, Kikuchi E, Maeda T, Nakashima J, Sugawara A, Ando T, Mizuno R, Nagata H, Miyajima A, Shigematsu N, Oya M (2013) A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy. J Urol 189:1014–1018. doi:10.1016/j.juro.2012.09.086 CrossRefPubMed Matsushima M, Kikuchi E, Maeda T, Nakashima J, Sugawara A, Ando T, Mizuno R, Nagata H, Miyajima A, Shigematsu N, Oya M (2013) A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy. J Urol 189:1014–1018. doi:10.​1016/​j.​juro.​2012.​09.​086 CrossRefPubMed
41.
Zurück zum Zitat Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG (2011) Prediction of erectile function following treatment for prostate cancer. JAMA 306:1205–1214. doi:10.1001/jama.2011.1333 CrossRefPubMed Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG (2011) Prediction of erectile function following treatment for prostate cancer. JAMA 306:1205–1214. doi:10.​1001/​jama.​2011.​1333 CrossRefPubMed
42.
Zurück zum Zitat Rizvi K, Hampson JP, Harvey JN (2002) Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 19:95–98CrossRefPubMed Rizvi K, Hampson JP, Harvey JN (2002) Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 19:95–98CrossRefPubMed
43.
Zurück zum Zitat Fonseca V, Seftel A, Denne J, Fredlund P (2004) Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 47:1914–1923CrossRefPubMed Fonseca V, Seftel A, Denne J, Fredlund P (2004) Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 47:1914–1923CrossRefPubMed
44.
Zurück zum Zitat McVary KT, Carrier S, Wessells H (2001) Smoking and erectile dysfunction: evidence based analysis. J Urol 166:1624–1632CrossRefPubMed McVary KT, Carrier S, Wessells H (2001) Smoking and erectile dysfunction: evidence based analysis. J Urol 166:1624–1632CrossRefPubMed
45.
Zurück zum Zitat Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z (1997) Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 9:123–126CrossRefPubMed Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z (1997) Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 9:123–126CrossRefPubMed
46.
Zurück zum Zitat Magli A, Giangreco M, Crespi M, Negri A, Ceschia T, De Giorgi G, Titone F, Parisi G, Fongione S (2012) Erectile dysfunction after prostate three-dimensional conformal radiation therapy. Strahlenther Onkol 188:997–1002CrossRefPubMed Magli A, Giangreco M, Crespi M, Negri A, Ceschia T, De Giorgi G, Titone F, Parisi G, Fongione S (2012) Erectile dysfunction after prostate three-dimensional conformal radiation therapy. Strahlenther Onkol 188:997–1002CrossRefPubMed
47.
Zurück zum Zitat Panje CM, Dal Pra A, Zilli T, D RZ, Papachristofilou A, Herrera FG, Matzinger O, Plasswilm L, Putora PM (2015) Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: a survey on patterns of practice. Strahlenther Onkol. doi:10.1007/s00066-015-0849-8 Panje CM, Dal Pra A, Zilli T, D RZ, Papachristofilou A, Herrera FG, Matzinger O, Plasswilm L, Putora PM (2015) Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: a survey on patterns of practice. Strahlenther Onkol. doi:10.​1007/​s00066-015-0849-8
48.
Zurück zum Zitat Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, Eble MJ (2011) Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 187:479–484. doi:10.1007/s00066-011-2249-z CrossRefPubMed Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, Eble MJ (2011) Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 187:479–484. doi:10.​1007/​s00066-011-2249-z CrossRefPubMed
Metadaten
Titel
Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients
verfasst von
P. M. Putora
D. Engeler
S. R. Haile
N. Graf
K. Buchauer
H. P. Schmid
L. Plasswilm
Publikationsdatum
01.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 3/2016
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0928-x

Weitere Artikel der Ausgabe 3/2016

Strahlentherapie und Onkologie 3/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.